IN148482B
(fr)
|
1977-06-03 |
1981-03-07 |
Pfizer |
|
CA1114379A
(fr)
*
|
1977-11-03 |
1981-12-15 |
Pfizer Corporation |
Piperidino-phtalazines
|
US4370328A
(en)
|
1977-11-03 |
1983-01-25 |
Pfizer Inc. |
Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines
|
US5001125A
(en)
*
|
1984-03-26 |
1991-03-19 |
Janssen Pharmaceutica N.V. |
Anti-virally active pyridazinamines
|
ATE49205T1
(de)
*
|
1984-09-14 |
1990-01-15 |
Asta Pharma Ag |
Substituierte benzylphthalazinon-derivate.
|
US4868179A
(en)
*
|
1987-04-22 |
1989-09-19 |
Cohn Jay N |
Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
|
US5106973A
(en)
*
|
1987-11-23 |
1992-04-21 |
Janssen Pharmaceutica N.V. |
Pyridzainamine derivatives
|
US4963676A
(en)
*
|
1988-02-09 |
1990-10-16 |
Georgia State University Foundation, Inc. |
Di-substituted phthalazines
|
JO1645B1
(en)
*
|
1989-12-26 |
1991-11-27 |
شركة جانسين فارماسوتيكا ان. في |
Pyridazine compounds are antibacterial viruses
|
ES2068413T3
(es)
*
|
1990-03-30 |
1995-04-16 |
Mitsubishi Chem Ind |
Derivados de 4-fenilftalazina.
|
US5100893A
(en)
*
|
1990-04-18 |
1992-03-31 |
Janssen Pharmaceutica N.V. |
Antipicornaviral pyridazinamines
|
TW279162B
(fr)
*
|
1991-09-26 |
1996-06-21 |
Mitsubishi Chem Corp |
|
CH683965A5
(it)
*
|
1993-02-19 |
1994-06-30 |
Limad Marketing Exp & Imp |
Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
|
US5716956A
(en)
*
|
1995-06-07 |
1998-02-10 |
Bearsden Bearsden Bio, Inc. |
Dihydrophthalazine antagonists of excitatory amino acid receptors
|
JP2001506653A
(ja)
|
1996-12-18 |
2001-05-22 |
ニューロゲン コーポレイション |
Crfレセプターと相互作用するイソキノリナミン及びフタルアジナミン誘導体
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
BR0009507A
(pt)
|
1999-03-30 |
2002-01-15 |
Novartis Ag |
Derivados de ftalazina para o tratamento de doenças inflamatórias
|
AR025068A1
(es)
*
|
1999-08-10 |
2002-11-06 |
Bayer Corp |
Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
|
CO5200835A1
(es)
*
|
1999-09-28 |
2002-09-27 |
Bayer Corp |
Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
|
US6689883B1
(en)
|
1999-09-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Substituted pyridines and pyridazines with angiogenesis inhibiting activity
|
DE19963607B4
(de)
*
|
1999-12-23 |
2005-12-15 |
Schering Ag |
Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
|
US7977333B2
(en)
*
|
2000-04-20 |
2011-07-12 |
Bayer Healthcare Llc |
Substituted pyridines and pyridazines with angiogenesis inhibiting activity
|
AR028782A1
(es)
*
|
2000-07-05 |
2003-05-21 |
Taisho Pharmaceutical Co Ltd |
Derivados heterociclicos tetrahidropiridino o piperidino
|
US6903101B1
(en)
|
2000-08-10 |
2005-06-07 |
Bayer Pharmaceuticals Corporation |
Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
|
GB0111078D0
(en)
*
|
2001-05-04 |
2001-06-27 |
Novartis Ag |
Organic compounds
|
US20030236259A1
(en)
*
|
2002-02-05 |
2003-12-25 |
Rolf Hohlweg |
Novel aryl- and heteroarylpiperazines
|
GB0223341D0
(en)
*
|
2002-10-08 |
2002-11-13 |
Groningen Acad Ziekenhuis |
Organic compounds
|
GB0310726D0
(en)
|
2003-05-09 |
2003-06-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
MXPA06005686A
(es)
*
|
2003-11-20 |
2006-08-17 |
Janssen Pharmaceutica Nv |
2-quinolinonas y 2-quinoxalinonas 7-fenilaquilo sustituidas como inhibidores de la poli(adp-ribosa)polimerasa.
|
EP1687277B1
(fr)
|
2003-11-20 |
2018-04-04 |
Janssen Pharmaceutica NV |
2-quinolinones et 2-quinoxalinones substituees par 6-alcenyle et 6-phenylalkyle utilisees comme inhibiteurs de la poly(adp-ribose) polymerase (parp)
|
NZ547193A
(en)
*
|
2003-12-05 |
2010-03-26 |
Janssen Pharmaceutica Nv |
6-Substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
|
CN1984904A
(zh)
*
|
2004-05-08 |
2007-06-20 |
神经能质公司 |
3-芳基-5,6-二取代哒嗪
|
JP4446047B2
(ja)
*
|
2004-06-02 |
2010-04-07 |
ケイティー コーポレーション |
アプリケーション及び管理サービスの提供、並びに使用者インターフェースの変更システム及びその方法
|
US7803795B2
(en)
*
|
2004-06-30 |
2010-09-28 |
Janssen Pharmaceutica N.V. |
Phthalazine derivatives as parp inhibitors
|
CN1980913B
(zh)
|
2004-06-30 |
2011-12-14 |
詹森药业有限公司 |
作为parp抑制剂的喹唑啉二酮衍生物
|
UA86237C2
(uk)
*
|
2004-06-30 |
2009-04-10 |
Янссен Фармацевтика Н.В. |
Похідні заміщеного 2-алкілхіназолінону як інгібітори parp
|
US20060014829A1
(en)
*
|
2004-07-16 |
2006-01-19 |
Nitromed, Inc. |
Methods for reducing hospitalizations related to heart failure
|
US8758816B2
(en)
|
2004-11-24 |
2014-06-24 |
Meda Pharmaceuticals Inc. |
Compositions comprising azelastine and methods of use thereof
|
NZ555501A
(en)
|
2004-11-24 |
2010-01-29 |
Medpointe Healthcare Inc |
Compositions comprising azelastine and methods of use thereof
|
US20070020330A1
(en)
|
2004-11-24 |
2007-01-25 |
Medpointe Healthcare Inc. |
Compositions comprising azelastine and methods of use thereof
|
EP2233470B1
(fr)
*
|
2005-07-04 |
2011-12-07 |
High Point Pharmaceuticals, LLC |
Antagonists du receptor histamine H3
|
JP2009524637A
(ja)
*
|
2006-01-27 |
2009-07-02 |
ファイザー・プロダクツ・インク |
アミノフタラジン誘導体化合物
|
US20080293724A1
(en)
*
|
2006-02-17 |
2008-11-27 |
Nitromed, Inc. |
Methods Using Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate
|
WO2007136626A1
(fr)
*
|
2006-05-16 |
2007-11-29 |
Nitromed, Inc. |
Formulations en doses solides de composés d'hydralazine
|
SG163547A1
(en)
*
|
2006-05-29 |
2010-08-30 |
High Point Pharmaceuticals Llc |
3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
|
EP2134691B1
(fr)
*
|
2007-03-08 |
2012-01-25 |
Janssen Pharmaceutica, N.V. |
Dérivés de quinolinone comme inhibiteurs de parp et de tank
|
UA100684C2
(uk)
*
|
2007-03-15 |
2013-01-25 |
Новартіс Аг |
Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
|
EP2014656A3
(fr)
*
|
2007-06-11 |
2011-08-24 |
High Point Pharmaceuticals, LLC |
Nouveaux antagonistes d'hétéocycliques h3
|
US8404713B2
(en)
*
|
2007-10-26 |
2013-03-26 |
Janssen Pharmaceutica Nv |
Quinolinone derivatives as PARP inhibitors
|
AU2009228945B2
(en)
*
|
2008-03-27 |
2013-05-02 |
Janssen Pharmaceutica Nv |
Quinazolinone derivatives as tubulin polymerization inhibitors
|
CN101981013B
(zh)
|
2008-03-27 |
2013-05-29 |
詹森药业有限公司 |
作为parp和微管蛋白聚合抑制剂的四氢菲啶酮和四氢环戊二烯并喹啉酮
|
AU2009241561B2
(en)
*
|
2008-04-29 |
2013-05-16 |
Eli Lilly And Company |
Disubstituted phthalazine hedgehog pathway antagonists
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
WO2010062507A1
(fr)
*
|
2008-11-03 |
2010-06-03 |
Eli Lilly And Company |
Antagonistes phtalazine disubstituée de la voie de signalisation hedgehog
|
ES2392759T3
(es)
|
2008-11-17 |
2012-12-13 |
Eli Lilly And Company |
Piridazina tetrasustituida como antagonistas de la vía Hedgehog.
|
AU2009314288B2
(en)
*
|
2008-11-17 |
2013-05-02 |
Eli Lilly And Company |
Tetrasubstituted pyridazines hedgehog pathway antagonists
|
US20180093956A1
(en)
*
|
2015-02-06 |
2018-04-05 |
Abbvie Inc. |
Substituted phthalazines
|
WO2018080216A1
(fr)
*
|
2016-10-28 |
2018-05-03 |
Daewoong Pharmaceutical Co., Ltd. |
Dérivé de phénylphtalazine, sa méthode de préparation et composition pharmaceutique le comprenant
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
WO2022165173A1
(fr)
*
|
2021-01-28 |
2022-08-04 |
The Scripps Research Institute |
Composés et leur utilisation pour le traitement de troubles neurodégénératifs, dégénératifs et métaboliques
|
CN115433163A
(zh)
*
|
2021-06-05 |
2022-12-06 |
药捷安康(南京)科技股份有限公司 |
Nlrp3炎症小体抑制剂及其应用
|
CN115417856A
(zh)
*
|
2021-09-30 |
2022-12-02 |
成都奥睿药业有限公司 |
一类取代杂芳酞嗪衍生物的药学用途及其制备方法
|